Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Marsha L. Pike"'
Autor:
Juan G. Ripoll, Sidna M. Tulledge-Scheitel, Anthony A. Stephenson, Shane Ford, Marsha L. Pike, Ellen K. Gorman, Sara N. Hanson, Justin E. Juskewitch, Alex J. Miller, Solomiia Zaremba, Erik A. Ovrom, Raymund R. Razonable, Ravindra Ganesh, Ryan T. Hurt, Erin N. Fischer, Amber N. Derr, Michele R. Eberle, Jennifer J. Larsen, Christina M. Carney, Elitza S. Theel, Sameer A. Parikh, Neil E. Kay, Michael J. Joyner, Jonathon W. Senefeld
Publikováno v:
mBio, Vol 15, Iss 5 (2024)
ABSTRACTAlthough severe coronavirus disease 2019 (COVID-19) and hospitalization associated with COVID-19 are generally preventable among healthy vaccine recipients, patients with immunosuppression have poor immunogenic responses to COVID-19 vaccines
Externí odkaz:
https://doaj.org/article/ecf5af76d7154c2cbf889ff5abdea430
Autor:
Tami K. Omdahl, Janelle L. Stenzel, Marsha L. Pike, Patricia M. Conlon, Tracy A. Barry, Tanya M. Brown, Kari L. Cambern, Kadi M. Davis, Kelly A. Fjerstad, Kevin K. Graner, Alexis K. Kuhn, Alison P. Larson, Amir B. Orandi, Emily L. Smith, Scott A. Soefje, Alan M. Janssen
Publikováno v:
Journal of Pediatric Hematology/Oncology Nursing. 40:185-192
Background: Many health care organizations offer pediatric infusions in outpatient infusion centers or, as in our organization, in a hospital-based outpatient Pediatric Infusion Therapy Center (PITC). When restrictions related to the COVID-19 pandemi
Autor:
Nischal Ranganath, John C O’Horo, Douglas W Challener, Sidna M Tulledge-Scheitel, Marsha L Pike, Michael O’Brien, Raymund R Razonable, Aditya Shah
Publikováno v:
Clinical Infectious Diseases. 76:e537-e539
In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2 patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of symptoms, which were generally mild, at a median of 9 days after
Autor:
Raymund R Razonable, John C O’Horo, Sara N Hanson, Richard F Arndt, Leigh L Speicher, Teresa A Seville, Scott T Hall, Marsha L Pike, Alexander Heyliger, Jennifer J Larsen, Ravindra Ganesh, Sidna M Tulledge-Scheitel
Publikováno v:
The Journal of infectious diseases. 226(10)
The effectiveness of bebtelovimab in real-world settings has not been assessed. In this retrospective cohort study of 3607 high-risk patients, bebtelovimab was used more commonly than nirmatrelvir-ritonavir for treatment of coronavirus disease 2019 (
Autor:
Nischal, Ranganath, John C, O'Horo, Douglas W, Challener, Sidna M, Tulledge-Scheitel, Marsha L, Pike, R, Michael O'Brien, Raymund R, Razonable, Aditya, Shah
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for coronavirus disease-2019, two patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of symptoms, which were generally mild, at median